A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

Completed · Phase 3 · Has a placebo group

Conditions studied: Spinal Muscular Atrophy

In brief

The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA). The secondary objective is to examine the safety and tolerability of nusinersen administered intrathecally to participants with later-onset SMA.

Key facts

Study ID
NCT02292537
Run by
Biogen
People needed
126
Starts
2014-11-24
Expected to finish
2017-02-20
Last updated by the study team
2021-02-17

Who can join

Age: 2 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.